INOVIO reported Q3 2026 financial results and highlighted the landmark FDA accelerated approval of VOCERYQ, the first-ever approved DNA medicine, for the treatment of Recurrent Respiratory Papillomatosis (RRP). The company recently completed a public offering raising $80.5 million in net proceeds to support the commercial launch of VOCERYQ, which is expected to be available for order in early 2027.
“We are delighted with the recent approval of VOCERYQ, which FDA described as a groundbreaking therapy that fights RRP at its source, not only its symptoms. INOVIO is now a commercial stage company with a primary goal to establish VOCERYQ as the preferred first-line immunotherapy for RRP patients.”
Dr. Jacqueline Shea, INOVIO’s President and Chief Executive Officer
“Our recently completed public offering provides additional financial resources to support a successful launch. Furthermore, this approval validates our DNA medicine platform and we are actively seeking partnerships to accelerate the development of other exciting candidates within our pipeline”
Dr. Jacqueline Shea, INOVIO’s President and Chief Executive Officer
Inovio Pharmaceuticals reported a net loss of $49.2 million for the third quarter of 2026, with total assets decreasing to $60.1 million from $74.3 million at year-end 2025. The company highlighted substantial doubt about its ability to continue as a going concern, noting that current working capital is only sufficient to fund operations through the fourth quarter of 2027.
INOVIO Pharmaceuticals entered into an underwriting agreement for a public offering of 58,747,235 shares of common stock and 12,681,337 pre-funded warrants. The underwriters fully exercised their option to purchase an additional 10,714,285 shares, bringing expected net proceeds to approximately $80.5 million. The capital will be used to support the company's development and commercialization of DNA medicines.
INOVIO Pharmaceuticals provided a preliminary financial update for the quarter ended September 30, 2026, estimating its cash, cash equivalents, and short-term investments at approximately $48.4 million. This disclosure serves as a selective operational update ahead of its full quarterly financial report.
The FDA granted accelerated approval for INOVIO's VOCERYQ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) to reduce the frequency of surgery in adults with Recurrent Respiratory Papillomatosis (RRP). This represents the first U.S. FDA-approved DNA medicine and validates INOVIO's platform technology, with a commercial launch expected in Q1 2027.
“With the approval of VOCERYQ, we believe our DNA medicine platform has the potential to transform the treatment paradigm for RRP by offering a patient-centric treatment option. VOCERYQ is designed to deliver what we understand matters most to patients, which is the reduction of the surgical burden caused by RRP.”
Dr. Jacqueline Shea, INOVIO’s President and Chief Executive Officer